{"id":27099,"date":"2025-01-29T11:59:13","date_gmt":"2025-01-29T10:59:13","guid":{"rendered":"https:\/\/idibell.cat\/?p=27099"},"modified":"2025-01-29T11:59:39","modified_gmt":"2025-01-29T10:59:39","slug":"nova-inversio-per-a-la-investigacio-contra-el-sarcoma-dewing","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2025\/01\/nova-inversio-per-a-la-investigacio-contra-el-sarcoma-dewing\/","title":{"rendered":"Nova inversi\u00f3 per a la investigaci\u00f3 contra el sarcoma d\u2019Ewing"},"content":{"rendered":"

Aptadel Therapeutics<\/span><\/a>, una spin-off de l\u2019Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL), rep mig mili\u00f3 de d\u00f2lars de la fundaci\u00f3 americana <\/span>Little Warrior<\/span><\/a> per finan\u00e7ar parcialment el programa d\u2019investigaci\u00f3 precl\u00ednica contra el sarcoma d\u2019Ewing. L\u2019objectiu principal del programa \u00e9s desenvolupar un tractament basat en tecnologia d\u2019ARN per combatre aquest c\u00e0ncer, que continua sent una de les causes de mort principals entre els infants a nivell global.\u00a0<\/span>\u00a0<\/span><\/p>\n

Com remarca la fundaci\u00f3 Little Warrior, \u00e9s vital invertir en la investigaci\u00f3 en c\u00e0ncers pedi\u00e0trics com el sarcoma d\u2019Ewing, donat que la inversi\u00f3 mundial afavoreix exageradament els c\u00e0ncers en edat adulta: per exemple, als Estats Units nom\u00e9s es destina un 4% del finan\u00e7ament anual per a recerca \u2014uns 195 milions de d\u00f2lars\u2014 a la investigaci\u00f3 oncol\u00f2gica pedi\u00e0trica. Aix\u00f2 vol dir que el c\u00e0ncer de pr\u00f2stata per si sol, que afecta predominantment a adults, ja rep m\u00e9s finan\u00e7ament que tots els c\u00e0ncers pedi\u00e0trics combinats. I els infants afectats per c\u00e0ncer segueixen sent molts, als qui no es pot desatendre i menys amb c\u00e0ncers tan agressius com el sarcoma d\u2019Ewing.\u00a0<\/span>\u00a0<\/span><\/p>\n

El sarcoma d\u2019Ewing \u00e9s una forma agressiva de c\u00e0ncer ossi, amb una gran tend\u00e8ncia a fer met\u00e0stasi, que afecta t\u00edpicament a infants i joves. Es pot desenvolupar tant als ossos com al teixit tou, per\u00f2 t\u00e9 prefer\u00e8ncia per formar-se als ossos llargs de les extremitats, la pelvis o la columna vertebral. En la majoria de casos apareix durant la pubertat, quan els ossos estan en un creixement continu i r\u00e0pid, i \u00e9s m\u00e9s f\u00e0cil que es produeixin errors durant la divisi\u00f3 cel\u00b7lular, accelerada <\/span>per se<\/span><\/i> en aquesta etapa, que alterin determinats gens. De fet, en aquest tipus de sarcoma, el gen que acostuma a estar afectat \u00e9s <\/span>EWS<\/span><\/i>, que per diversos errors dels quals es desconeix l\u2019origen, acaba fusionat amb altres gens i crea un gen de fusi\u00f3 que no funciona com hauria de fer-ho. En el 90% dels casos, el company d\u2019<\/span>EWS<\/span><\/i> \u00e9s el gen <\/span>FLI1<\/span><\/i>, per\u00f2 en el 10% restant canvia de parella (<\/span>ERG<\/span><\/i>, <\/span>ETV1<\/span><\/i>, <\/span>EA1F<\/span><\/i>, …).\u00a0<\/span>\u00a0<\/span><\/p>\n

La manca d\u2019investigaci\u00f3 en Ewing s\u2019evidencia en els relativament pocs aven\u00e7os que s\u2019han fet des que es va posar nom i cognoms a aquest c\u00e0ncer. Tot i que es va caracteritzar com a tumor maligne el 1920, encara se\u2019n desconeix la causa. No se n\u2019ha identificat cap causa gen\u00e8tica, ambiental o de qualsevol altres tipus, i roman avui en dia com un c\u00e0ncer que sembla lligat a l\u2019atzar. A part, el tractament que s\u2019aplica no ha canviat en quasi 40 anys i inclou alguns dels f\u00e0rmacs m\u00e9s t\u00f2xics del mercat.\u00a0<\/span>\u00a0<\/span><\/p>\n

Precisament per aix\u00f2, fundacions com Little Warrior i programes d\u2019investigaci\u00f3 relacionats amb el Sarcoma d\u2019Ewing, com el que va donar lloc a la creaci\u00f3 d\u2019Aptadel Therapeutics, s\u00f3n vitals. \u00c9s necessari trobar tractaments alternatius que siguin m\u00e9s efica\u00e7os i menys t\u00f2xics que els actuals, per rebaixar els efectes adversos derivats de la ter\u00e0pia que pateixen els infants afectats. L\u2019aposta d\u2019Aptadel es basa en els apt\u00e0mers d\u2019RNA, petits fragments d\u2019\u00e0cids nucleics que s\u00f3n capa\u00e7os de recon\u00e8ixer i unir-se selectivament a dianes molt concretes. Per la manera d\u2019actuar recorden als anticossos del nostre sistema immunitari (per aix\u00f2 reben el sobrenom d\u2019anticossos qu\u00edmics), per\u00f2 molt m\u00e9s flexibles i f\u00e0cils de modificar, de manera que es poden dissenyar per a qu\u00e8 s\u2019acoblin a la mol\u00e8cula que interessi (agents terap\u00e8utics, nanopart\u00edcules, …). Aix\u00f2 els dona un gran potencial d\u2019aplicaci\u00f3 terap\u00e8utica i diagn\u00f2stica.\u00a0<\/span>\u00a0<\/span><\/p>\n

\u00a0<\/span><\/p>\n

\u00a0<\/span><\/p>\n

L\u2019Institut d’Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) \u00e9s un centre de recerca en biomedicina creat l\u2019any 2004. Est\u00e0 participat per l’Hospital Universitari de Bellvitge i l\u2019Hospital de Viladecans de l’Institut Catal\u00e0 de la Salut, l’Institut Catal\u00e0 d’Oncologia, la Universitat de Barcelona i l\u2019Ajuntament de l\u2019Hospitalet de Llobregat.<\/span><\/i>\u00a0<\/span><\/p>\n

L\u2019IDIBELL \u00e9s membre del Campus d’Excel\u00b7l\u00e8ncia Internacional de la Universitat de Barcelona HUBc i forma part de la instituci\u00f3 CERCA de la Generalitat de Catalunya. L’any 2009 es va convertir en un dels cinc primers centres d\u2019investigaci\u00f3 espanyols acreditats com a institut d\u2019investigaci\u00f3 sanit\u00e0ria per l\u2019Instituto de Salud Carlos III. A m\u00e9s, forma part del programa \u201cHR Excellence in Research\u201d de la Uni\u00f3 Europea i \u00e9s membre de EATRIS i REGIC. Des de l\u2019any 2018, l\u2019IDIBELL \u00e9s un Centro Acreditado de la Fundaci\u00f3n Cient\u00edfica AECC (FCAECC).<\/span><\/i>\u00a0<\/span><\/p>\n

\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

Aptadel Therapeutics rep mig mili\u00f3 de d\u00f2lars per un programa d’investigaci\u00f3 precl\u00ednica contra el sarcoma d’Ewing<\/p>\n","protected":false},"author":8,"featured_media":27101,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[332,447,398],"tags":[],"class_list":["post-27099","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cancer","category-p-de-mecanismes-molelculars-i-terapia-experimental-en-oncologia-oncobell","category-sarcoma"],"publishpress_future_action":{"enabled":false,"date":"2025-02-06 19:48:16","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/27099","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=27099"}],"version-history":[{"count":1,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/27099\/revisions"}],"predecessor-version":[{"id":27102,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/27099\/revisions\/27102"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/27101"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=27099"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=27099"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=27099"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}